INTRODUCTION
Epidemiology, clinical intervention, and animal model studies have defined the negative health consequences of air pollution on respiratory disease. [1] [2] [3] [4] Urban particulate matter (PM) is a major component of air pollution, and is broadly categorized as coarse (PM 10 ), fine (PM 2.5 ), or ultrafine (PM 0.1 ), based on mean particle size fractions that are o10, 2.5, or 0.1 mm, respectively. PM varies based on geography, season, and proximity to roadways, and acts as a carrier for additional components of air pollution including polyaromatic hydrocarbons, elemental metals, and allergens. 5, 6 Deposition of PM with adsorbed air pollution components into the upper and lower airway respiratory mucosa 7 induces airway epithelial cell innate immune responses, [8] [9] [10] [11] [12] which may be relevant in facilitating allergic sensitization and exacerbation of existing airway disease. 4, [12] [13] [14] We demonstrated that PM facilitates innate immune responses through the nucleotide-binding domain, leucine-rich repeat protein 3 inflammasome, 8 but this innate immune sensor was not required for PM-facilitated allergic sensitization. 12 Thus, the mechanism governing this PMinduced sensitization remains unknown.
The respiratory mucosa possesses several defenses against PM exposure and the oxidative effects of air pollution. 8, 11, 15, 16 These include tight junctions between epithelial cells, expression of pattern recognition receptors linked to innate immune responses, production of antimicrobial peptides, and secretion of a complex and viscous mucus layer. The mucus layer contains a variety of protective innate immune mediators and antioxidants, including uric acid. Uric acid is generated by xanthine dehydrogenase (XDH) as a metabolite of purine metabolism. 17 Conversely, it is catabolized by uricase, which is restricted to the liver in most mammals including mice. 18 In humans, mutations over millions of years have lead to a nonfunctional uricase enzyme, resulting in elevations in circulating uric acid. 19 In healthy humans, uric acid has been identified in upper and lower airway washings, [20] [21] [22] suggesting that a secretory mechanism may exist; however, this has not been identified to date. Uric acid can promote either beneficial or harmful effects depending on its concentration and whether in solution or solid state. Soluble uric acid is a potent antioxidant and free radical scavenger. 21, 23 Conversely, at higher concentrations uric acid can precipitate into crystals that promote the activation of the nucleotide-binding domain, leucine-rich repeat protein 3 inflammasome and dendritic cells. [24] [25] [26] Despite the clear beneficial and harmful roles that uric acid can play, how its levels are regulated in the respiratory mucosa under basal and stimulated conditions remains unknown.
Previous reports have demonstrated in mice that allergic sensitization to house dust mite (HDM) requires both Toll-like receptor 4 (TLR4) expression on airway epithelial cells and the presence of uric acid. [27] [28] [29] We therefore hypothesized that (i) airway epithelial cells produce and secrete uric acid under basal and stimulated conditions and (ii) PM exposure induces respiratory mucosal uric acid production and secretion that is required for allergic sensitization.
We found that mucosal production of uric acid is induced by inhaled insults associated with allergic sensitization, and not by several other challenges. Uric acid was crucial in mediating the development of PM-facilitated allergic airway disease independent of TLR4, and regulated antigen-specific T-cell proliferation. The expression of XDH and a candidate uric acid transporter, multi-drug resistance protein 4 (MRP4), was identified and characterized in primary human airway epithelial cells and lung tissue. Inhibition of this transporter attenuates basal and stimulated uric acid production from airway epithelial cells, which was independent of cell death. Collectively, our results demonstrate that PM and HDM induce the production of uric acid through a novel airway mucosal secretion system that may have a key role in allergic sensitization.
RESULTS
Uric acid is selectively induced in mouse lungs by PM 10 and HDM but not other challenges
We have shown that PM 10 can facilitate allergic sensitization 12 and can be found within airway epithelial cells in mouse lung following exposure. 8 We therefore tested whether this occurs with the induction of uric acid. We exposed mice to a single intranasal dose of PM 10 with and without uricase followed by bronchoalveolar lavage (BAL) 24 h later. PM 10 -induced uric acid production in the lung was inhibited by uricase ( Figure 1a) . Immunohistochemical staining for uric acid revealed robust positive staining in the airway epithelium under both basal and stimulated conditions (Figure 1b) . We also observed staining in smooth muscle tissue in mouse lung. We next evaluated several other stimuli on lung uric acid production. Exposure to HDM induced similar levels of uric acid ( Figure 1c ) compared with PM 10 ( Figure 1a) . In contrast, exposure to viral (influenza), bacterial (S. pneumoniae), or inflammatory/fibrotic (bleomycin) challenges had no effect on uric acid secretion (Figure 1d-f ) despite inducing diverse lung pathologies (data not shown). Although exposure to lipopolysaccharide and ovalbumin (OVA) induced uric acid secretion in the lung, the levels did not reach statistical significance (P40.05, Figure 1g ). Thus, we conclude that uric acid is selectively induced in mouse lungs in response to PM 10 and HDM, which are environmental stimuli associated with allergic sensitization.
Uric acid production in the lung during PM 10 exposure facilitates allergic sensitization
To examine the consequences of PM 10 -induced uric acid production on allergic sensitization, we used a model of mucosal sensitization and challenge using PM 10 and OVA ( Figure 2a) . 12 Concurrent exposure of mice to PM 10 /OVA induced allergic sensitization, as indicated by elevations in total BAL cells and eosinophils, OVA-specific immunoglobulins, lung Th2 cytokine gene expression, and goblet cell metaplasia (Figure 2b-q) . Uricase instillation in the lungs during PM 10 /OVA co-exposure inhibited the development of an allergic phenotype with attenuation of all outcome measurements, with the exception of IFN-g gene expression in the lung (Figure 2b-q) . OVA exposure in the absence of PM 10 induced increases in markers of allergic sensitization, which were also attenuated by uricase treatment (Supplementary Figure S1 online).
PM 10 -facilitated allergic sensitization is independent of TLR4
It is possible that endotoxin present in our reagents could confound results obtained from a model of PM 10 -facilitated allergic sensitization to OVA with uricase treatment. Furthermore, reports have demonstrated that uric acid production relevant in allergic sensitization is downstream of TLR4. 28, 30 Using Tlr4 À / À mice and our model of OVA/PM 10 co-exposure (Figure 2a) , we demonstrate that PM 10 -facilitated allergic sensitization is independent of TLR4 ( Figure 3) . Furthermore, the activity of uricase in attenuating PM 10 -facilitated allergic sensitization is also independent of TLR4.
PM 10 induces an increase in lung group 2 innate lymphoid cells which is not attenuated by uricase treatment Recently, our group has linked group 2 innate lymphoid cells (ILC2s) to allergic sensitization at the respiratory mucosa surface. 31 Our PM 10 /OVA model demonstrated an elevation in IL-33 gene expression, a key cytokine responsible for ILC2 maturation and function. We therefore pursued the possibility that PM 10 /OVA exposure was inducing ILC2s in our model in a uric acid-dependent mechanism. PM 10 /OVA exposure induced a uric acid increase associated with an increase in lung ILC2s positive for intracellular IL-5 ( Figure 4) . Uricase treatment attenuated PM 10 /OVA induced uric acid, although no effect was observed on ILC2 numbers or IL-5 cytokine expression. The results suggest that ILC2s are not a key player mediating allergic sensitization in a model of PM 10 /OVA exposure.
Uricase treatment attenuates antigen-specific CD4 T-cell proliferation
Our observations that uricase inhibited in vivo PM 10 -facilitated allergic sensitization suggested that the downstream activity of CD4 þ T cells could also be modified. Thus, we examined the influence of PM 10 , and uricase treatment on CD4 þ T-cell and regulatory T cell (Treg) activation. 32, 33 Proliferation of CD4 þ T cells was restricted to the draining mediastinal lymph nodes and was induced by OVA/PM 10 exposure, while uricase treatment attenuated this response (Figure 5b) . We quantified the percentage of carboxyfluorescein succinimidyl ester (CFSE)-labeled CD4 þ T cells in each cycle of cell division and demonstrated that OVA/PM 10 exposure resulted in greater proliferation than OVA/PM 10 /uricase treatment ( Figure 5c ). Our results suggest that uricase treatment attenuates antigenspecific CD4 þ T-cell proliferation. We next investigated the influence of uric acid on Tregs. OVA/PM 10 exposure induced an increase in exogenous (CFSE þ ) Foxp3 þ CD4 þ Tregs from the adoptively transferred cells, which was not altered by uricase treatment (Figure 5d) . No changes in endogenous (CFSE À ) Foxp3 þ CD4 þ Tregs were observed following OVA/PM 10 exposure with or without uricase treatment (Figure 5e ). In summary, these results suggest that PM 10 exposure induces a selective, uricase-sensitive antigen-specific CD4 þ T-cell proliferation that is independent of changes in Treg numbers.
Human airway epithelial cells express a functional uric acid production and secretion system Uric acid has been detected in both lung 22, 28 and nasal 21 washings in healthy humans, although the source(s) remain unknown. On the basis of these observations and our in vivo immunohistochemistry results (Figure 1b) , we assessed whether human airway epithelial cells express a uric acid secretory system that is responsible for basal production that can be further activated by PM 10 . We found that unstimulated human airway epithelial cells produce uric acid and the enzyme responsible for its production, XDH (Figure 6a,b) . Our observation of unstimulated uric acid production suggested that this could be an active process that is independent of cell death. In kidney tubular epithelial cells, MRP4 utilizes ATP to actively transport uric acid for secretion in the urine. 34 We therefore evaluated MRP4 as a candidate uric acid transporter in airway epithelial cells and found its expression in both human airway epithelial primary cells and cell lines (Figure 6b) . We subsequently performed confocal microscopy imaging for XDH and MRP4 protein expression in human airway epithelial cells (Figure 6c,d ). XDH expression appeared to be diffuse throughout the cytoplasm of airway epithelial cells, whereas MRP4 expression was observed in punctate foci scattered throughout the cytoplasm. We confirmed in situ protein expression of XDH and MRP4 in human lungs by immunohistochemistry (Figure 6e ). XDH staining was diffuse throughout all cell phenotypes in the airway epithelium, whereas MRP4 staining was restricted to basal cells. Collectively, these studies supported the hypothesis that human airway epithelial cells express a uric acid secretory system.
To determine whether PM 10 or HDM impacted the expression of XDH and MRP4, we exposed airway epithelial cells to these insults and assessed gene expression. We demonstrate that XDH and MRP4 gene expression is not changed following either environmental exposure in HBEC-6KT human airway epithelial cells (Figure 7a ). We next determined whether the uric acid secretory system was functional, by exposing human airway epithelial cells to PM 10 and measuring uric acid production. Control experiments with PM 10 and uric acid in the absence of cells demonstrated an interaction between these components resulting in a compromised ability to detect a uric acid signal (Supplementary Figure S2) . Our PM 10 (ref. 35 ) contains iron, which may be an important confounding variable as this metal can chelate uric acid, 36 potentially impacting our method of detection in in vitro experimental systems. We therefore used HDM as a trigger (Figure 1c ). HDM exposure resulted in a trend for a time-dependent increase in uric acid production from primary human airway epithelial cells (Figure 7b ). To implicate MRP4 as the functional transporter for uric acid, we used MK-571, a cysteinyl leukotriene receptor antagonist, that also blocks MRP4 function. 37 Exposure to HDM for 24 h induced a significant uric acid production in HBEC-6KT human airway epithelial cells ( Figure 7c ) and this was independent of cell death (Figure 7d) . Moreover, MK-571 treatment attenuated both basal and HDM-induced uric acid production in HBEC-6KT human airway epithelial cells (Figure 7c ). To confirm these findings, we used different classes of pharmacological compounds that also block MRP4 function. 38 Both losartan, an angiotensin II receptor antagonist, and indomethacin, a nonselective cyclooxygenase antagonist, inhibited HDM-induced uric acid production in HBEC-6KT (Figure 7e,f) . To further confirm the functional properties of MRP4 in human airway epithelial cells, we performed experiments probing cyclic AMP secretion in HBEC-6KT human airway epithelial cells. Cyclic AMP, like uric acid, is a known endogenous substrate for MRP4. 38 We demonstrate that HBEC-6KT human airway epithelial cells are capable of secreting cyclic AMP (Supplementary Figure S3A ) and this is inhibited with MK-571 (Po0.05). Interestingly, however, neither PM 10 nor HDM induced cyclic AMP secretion in HBEC-6KT human airway epithelial cells (Supplementary Figure S3B) .
Previous studies suggest that uric acid is upstream of IL-1a and HMGB1 cascade and that these mediators temporally precede elevations of IL-33 and TSLP during allergic sensitization. 30, 39 We therefore examined whether uric acid alone could induce cytokine production from airway epithelial cells. Exposure of primary human airway epithelial cells to soluble uric acid did not induce any production of either IL-1a or HMGB1 above control (Supplementary Figure S4) . In experiments with airway epithelial cells exposed to HDM that triggered detectable uric acid, we were unable to detect any IL-33 and TSLP in any control or experimental conditions (data not shown).
Collectively, our data support the presence and function of an active MRP4-mediated uric acid secretion system in human airway epithelial cells, which may be a mechanistic pathway for uric acid production in vivo in response to PM 10 and allergens.
DISCUSSION
We demonstrate for the first time that air pollution PM 10 induces uric acid production in the respiratory mucosa. We found that airborne allergens such as HDM also induce uric acid production, while other disease triggers including viral or bacterial infection and fibrotic stimuli do not. Further, uric acid secretion occurs at least in part, through a previously uncharacterized mucosal uric acid secretion system in airway epithelial cells. Thus, air pollution and allergens may induce uric acid production that facilitates allergic sensitization and asthma pathogenesis. Our work sets the stage for further investigation of the clinical relevance of the respiratory epithelial cell uric acid secretion system in lung health and disease.
A link has been recently established between uric acid production and allergic sensitization in models of intraperitoneal injection of OVA/alum and mucosal instillation of HDM. 28 Additional reports show that uric acid crystals influence dendritic cells in vitro and allergic sensitization in vivo. 25, 26, 28 These observations led us to hypothesize that mucosal uric acid production is the underpinning mechanism of PM 10 -facilitated allergic sensitization. Our results demonstrate that PM 10 can indeed induce uric acid production to levels similar to those reported for HDM, 28 and that the airway epithelium is a significant source. Expression of uric acid was also observed in smooth muscle, but at levels much lower than in airway epithelium. This suggests that the airway epithelium is likely the dominant source of uric acid in lung tissue. 
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In contrast to PM 10 and HDM exposures, which are associated with allergic sensitization, exposure to insults that lead to other clinically relevant forms of lung inflammation, innate immune responses, and pathology did not induce uric acid release. Exposure to influenza, S. pneumoniae, or bleomycin have all been associated with cell death, 40-44 but we did not observe an increase in lung uric acid in any of these models. Our data provide strong evidence that a selective production of epithelial uric acid occurs in response to air pollution or allergen and that lung pathology associated with cell death does not lead to sustained, significant, elevations in uric acid.
Pulmonary uric acid production has been linked to Th2-skewed allergic sensitization to HDM, 28 although the mechanism of its release and/or cellular source has not been clearly defined. We demonstrate that PM 10 can induce similar increases in lung uric acid production, while we, and others, have reported the ability of PM 10 to facilitate Th2-skewed allergic sensitization. [12] [13] [14] We therefore reasoned that an intervention strategy that inhibited PM 10 -induced uric acid in the respiratory mucosa should be effective in preventing allergic sensitization. To test this, we used intranasal uricase treatment to selectively reduce uric acid in the mucosal environment during the sensitization phase of an OVA/PM 10 co-exposure model. 12 Uricase treatment completely attenuated allergic sensitization and the development of Th2-skewed immune responses. The concentrations of uric acid detected in our in vivo studies (10-20 mM or 1-2 mg ml ), suggesting that crystal formation in the lung is likely not the mechanism behind the response to PM 10 . Although we currently cannot rule out local crystal formation in microenvironments, it has been reported that formation of uric acid crystals at supersaturating concentrations requires more than a week. 45 On the basis of our data and current knowledge, the downstream consequences of PM 10 -induced uric acid production may be more closely linked to the soluble form of this of this molecule. Collectively, our data show that mucosal production of uric acid occurs in response to PM 10 and this is a critical molecule required for PM 10 -facilitated allergic sensitization.
To pursue the possibility that uricase treatment could have off-target effects independent of breaking down uric acid, additional experiments were performed with added controls. In our models, PM 10 exposure induced a significant amount of lung uric acid (Figure 1a , Po0.05), while a trend for increased uric acid was observed for OVA exposure (Figure 1g, P40.05 ). Uricase treatment in both the OVA alone and OVA þ PM 10 exposure groups prevented allergic sensitization. The mechanism responsible for this is likely attributable to the breakdown of uric acid induced by PM 10 and OVA, although the low levels of uric acid induced by OVA allude to the potential that uricase may also be having some off-target effects that are capable of suppressing Th2 immunity, independent of uric acid. 46 Several mouse studies examining lung inflammation and remodeling have used uricase as a preclinical strategy to attenuate levels of lung uric acid. 28, 47, 48 We have used a similar strategy and demonstrate the ability of uricase to break down uric acid in BAL fluid of PM 10 -challenged mice (Figure 1a) . Commercial uricase used by these studies contains endotoxin (841 EU ml À 1 ), which may provide a confounding factor for data interpretation. Furthermore, reports have demonstrated that uric acid production relevant in allergic sensitization is downstream of TLR4. 28, 30 We addressed these issues by performing experiments in Tlr4 À / À mice and demonstrate that both PM 10 -facilitated allergic sensitization to OVA and uricase attenuation of this process are independent of TLR4. Alternative off-target effects of uricase 49 and TLR4-independent pathways leading to uric acid production may exist, but a complete characterization of these possibilities is beyond the scope of the present paper.
Elevations in airway epithelial cell-derived cytokines including IL-33, TSLP, and IL-25 have been linked to ILC2s development and function. 31 To investigate whether ILC2s were induced in our PM 10 /OVA exposure model, we performed flow-cytometric analysis of ILC2 population number and expression of IL-5. We demonstrate that PM 10 /OVA exposure induces an expansion of lung ILC2s that are positive for IL-5, but these are not influenced by uricase treatment, despite changes in lung uric acid levels. Collectively, these data suggest that ILC2s are induced in our model of PM 10 /OVA exposure, but they are not key players in the induction of allergic sensitization that is attenuated with uricase treatment.
A possible interpretation of our findings is that soluble uric acid attenuates dendritic cell activation upon PM 10 exposure, impairing the development of Tregs or Th1/Th17-skewed inflammatory responses, resulting in Th2-skewed allergic sensitization. 33, 50, 51 However, uricase did not change lung IFN-g (Th1) responses or Treg numbers, suggesting that this is not the case. We therefore explored the alternate possibility that uric acid acts directly on T cells to induce proliferation as has been reported. 32 Adoptive transfer experiments using CFSE-labeled antigen-specific OTII CD4 þ T cells suggest that uricase treatment attenuates proliferation of these cells, although it remains unknown whether this is a direct or indirect effect of uric acid. It is possible that uric acid influences OTII CD4 þ T-cell proliferation directly by acting on T cells or indirectly by acting on dendritic cells, independent of Treg cells. Future in vitro and in vivo studies using direct uric acid treatment on T cells in culture or adoptive transfer of antigenpulsed dendritic cells, respectively, would extend our original observations. Uric acid has been detected in nasal and airway washings of healthy human subjects, although the mechanism governing its production and secretion remains uncharacterized. 21, 22 XDH is the enzyme responsible for the endogenous production of uric acid, and our data identify the expression of this enzyme in airway epithelial cells. We then focused on possible mechanisms for uric acid secretion based on the previous analyses of uric acid transporters in kidney tubular epithelial cells. 34, 52 Of the several known uric acid transporters, only MPR4 expression was reported to be restricted to the apical side of kidney tubular epithelial cells, 34 and so we focused on this candidate. We demonstrate that MRP4 is expressed in human airway epithelial cells in vitro and in situ and its expression is not impacted by either PM 10 or HDM exposure. Our findings confirm the only other report demonstrating MRP4 protein expression in human airway epithelial cells, 37 although the function this group attributed to this protein was for prostaglandin transport.
We next sought to determine whether uric acid detected in vivo following PM 10 exposure was produced from airway epithelial cells using this production and secretion system. In control experiments, we spiked known concentrations of uric acid with the dose of PM 10 used for our in vitro studies (Supplementary Figure S2) . 8 Unfortunately, PM 10 interfered with detection of uric acid, precluding its use in subsequent in vitro experiments. The mechanism of how PM 10 interferes with uric acid detection remains unknown and may involve adsorption of uric acid to the PM 10 , oxidation of uric acid by PM 10 , or PM 10 interference with the uric acid assay chemistry. Iron content in PM 10 (ref. 35 ) may be an important confounding variable as this metal can chelate uric acid, 36 potentially impacting our method of detection in our in vitro experimental system. Since we (Figure 1c) , and others, 28 have shown that HDM induces uric acid production in mouse lungs, we exposed human airway epithelial cells to HDM and observed increased uric acid release. Previous studies have implicated cell death as a source of uric acid release while not addressing the possibility of active cell processes involving transporters. 26, 45 To further support active transport as the mechanism of uric acid release in the respiratory mucosa, we performed an intervention study with MK-571, which inhibits MRP4 activity. 37 MK-571 attenuated basal and HDM-induced uric acid production by airway epithelial cells, which was independent of changes in lactate dehydrogenase (LDH) levels, further suggesting an active release mechanism that is independent of cell death. To selectively interrogate the role of MRP4 in transport of uric acid, we attempted siRNA experiments. We were unable to achieve significant knockdown even after 48 h exposure to a cocktail of siRNA (data not shown). Accordingly, we used a pharmacological approach with several different classes of compounds reported to inhibit MRP4 activity. 38 Exposure to the clinically used drugs losartan and indomethacin 38 also inhibited MRP4-mediated uric acid release, further supporting a role for this transporter in human airway epithelial cells.
Additional experiments were performed to determine whether uric acid operated upstream of IL-1a, HMGB1, IL-33, and TSLP, as these immune mediators have been implicated in bridging innate and adaptive immune responses. 30, 39 Exposure of primary human airway epithelial cells directly to uric acid failed to induce production of any of these mediators in our model system. Collectively, our results demonstrate that uric acid production and transport through MRP4 does not result in autocrine or paracrine signaling and production of IL-1a, HMGB1, IL-33, or TSLP from human airway epithelial cells.
A limitation of our study is that we have not demonstrated that in vivo production and transport of uric acid in response to PM 10 and HDM exposure is mediated through the same mechanism, despite our data and that of others showing uric acid expression in airway epithelial cells in mice. 28 For our in vitro studies, we used HDM as a stimulus for uric acid production and transport in airway epithelial cells as PM 10 interfered with measurements. Our data clearly demonstrate that airway epithelial cells can produce and transport uric acid through MRP4. Further studies are required to confirm whether the mechanisms by which PM 10 and HDM stimulate uric acid production and secretion are conserved.
In summary, our studies demonstrate that (i) mucosal production of uric acid is selective for inhaled insults that are associated with allergic sensitization, (ii) in vivo mucosal production of uric acid is crucial in mediating the development of PM 10 -facilitated allergic airway disease and the regulation of antigen-specific T-cell proliferation, and (iii) the airway epithelium is the primary source of active uric acid production and secretion. To our knowledge, this study presents the first evidence of a uric acid transport system in the human airway epithelium. Collectively, our work highlights the importance of air pollution-and allergen-induced mucosal production of uric acid in the context of allergy and asthma and establishes a foundation to pursue the clinical relevance of the respiratory epithelial cell uric acid secretion system in lung health and disease.
METHODS
Mice. Female C57BL/6 mice 6-8 weeks of age were purchased from Jackson Laboratories (Bar Harbor, ME) for all PM 10 and HDM exposure experiments, or from the Central Animal House at the University of Newcastle for S. pneumoniae, and bleomycin exposure experiments. For influenza H1N1 A/PR/8/34 exposure, wild-type BALB/c mice aged 6-8 weeks of age were purchased from the Central Animal House at the University of Newcastle. Tlr4
À / À mice were on a C57Bl/6 background and bred at the UBC Biomedical Research Facility.
PM 10 characteristics. We used EHC93 PM 10 collected by Health Canada as described previously, 6, 35 which is comparable to National Institute for Standards and Technology standard reference material (NIST-SRM)-1649. 6, 35 Reagents. Human airway epithelial cell lines and primary cells were grown as described previously. 8 Chicken egg white OVA grade V, uricase, and uric acid were purchased from Sigma (Oakville, Ontario Canada). PE-conjugated CD25 (PC61.5), Sca-1 (D7), APC-conjugated IL-5, and APC-efluor780 efluor650-conjugated CD90.2 (53-2.1) were purchased from eBioscience (San Diego, CA). FITC-conjugated ST2 (DJ8) was purchased from MD Bioproducts (St Paul, MN). Pacific Blue-conjugated CD45 (I3/2) was produced in-house. Intracellular cytokine staining was performed with the Cytofix/Cytoperm kit (BD Bioscience, Mississauga, Ontario, Canada), and viable cells were identified using the efluor-450, -506, or -780 fixable viability dye (eBioscience). Lung ILC2s were identified as Lineage-CD45 þ CD90.2 þ CD25 þ Sca1 þ ST2 þ viable cells and gated for IL-5 expression based on FMO controls. efluor450-conjugated FoxP3 antibody (FJK-16s) and Foxp3 staining buffer were purchased from eBioscience. The following antibodies for serum immunoglobulin analysis were purchased from BD Pharmingen (Mississauga, Ontario, Canada): HRP-conjugated anti-mouse IgG1 and IgG2a antibodies, and biotin-conjugated anti-mouse IgE and streptavidin-conjugated HRP were obtained from Jackson Immuno Research (West Grove, PA). HDM extract was purchased from Greer Laboratories (Lenoir, NC) and prepared as previously described. 28, 53 Uric acid was detected using an Amplex Red Uric Acid kit as per the manufacturer's directions (Molecular Probes/Invitrogen, Burlington, Ontario, Canada) or the Abcam kit (ab65344) (Abcam, Toronto, Ontario, Canada). Uric acid antibody (AB53000) used previously, 28 XDH (AB85541) and MRP4 (AB15602) antibodies were purchased from Abcam and immunohistochemistry reagents were from DAKO (Burlington, Ontario, Canada). LDH assay for cell viability was purchased from Cayman Chemical (Burlington, Ontario, Canada). Influenza H1N1 A/PR/8/34 strain and S. pneumoniae serotype 2 (strain d39) were obtained and prepared as described previously. 54 Bleomycin was purchased from MP Biomedicals (Seven Hills, NSW, Australia). Losartan, indomethacin, IBMX, and forskolin were purchased from Cayman Chemical. The cAMP parameter assay was purchased from R&D Systems (Mississauga, Ontario, Canada).
Human tissue and in vitro experiments. A minimally immortalized human airway epithelial cell line (HBEC-6KT) was generated from a healthy non-smoker by expression of human telomerase reverse transcriptase and cyclin-dependent kinase 4 (ref. 55) that we have described previously. 8, 12 For human gene expression analysis and basal production of uric acid, primary human airway epithelial cells from healthy donors were isolated from bronchial brushings. Human airway sections were from lungs donated for medical research from the University of British Columbia. For functional experiments, airway epithelial cells were exposed to 50 mg of HDM in 1 ml of media for 24 h followed by uric acid and LDH measurement. MK-571 has been reported to inhibit MRP4 channel activity at 20 mM, 37 losartan at 10 mM, and indomethacin at 10 mM. Cells were preincubated with antagonists or DMSO diluent for 30 min before exposure to HDM or media control. For cyclic AMP secretion assays, HBEC-6KT at 80% confluency was exposed to IBMX (2 mM) for 2 h before exposure to experimental conditions. Following 2 h IBMX exposure, cells were exposed for 2 h with MK-571 (20 mM) or DMSO control. After these two incubation steps, HBEC-6KT was exposed to forskolin at 10 mM with cell-culture supernatants collected 6 h later for assessment of secreted cyclic AMP.
In vivo experiments. For uricase intervention experiments during PM 10 exposure, mice were exposed to a single intranasal dose of PM 10 (200 mg) or PM 10 (200 mg)/uricase (10 U) in 50 ml sterile saline, followed by killing 24 h later. For uric acid analysis studies with HDM, mice were exposed to a single intranasal dose of 100 mg per 50 ml HDM in sterile saline, followed by killing 2 h later. 28 For influenza virus exposure, mice were inoculated intranasally with 8 plaque forming unit (p.f.u.) of the mouse-adapted H1N1 influenza virus A/PR/8/34 in 50 ml of saline, controls were sham-inoculated with vehicle as described previously. 54 Mice were killed at 3 days post infection. For S. pneumoniae exposure, mice were inoculated with a single intratracheal dose of 2 Â 10 6 p.f.u. in 40 ml of saline, followed by killing 8 h later as described previously. 56 For bleomycin exposure, mice were administered a single 0.05 U dose of bleomycin sulfate intranasally and killed at various time points. 57 For OVA alone exposure, mice were administered a single 100 mg per 50 ml dose, followed by killing 24 h later. For lipopolysaccharide exposure, mice were administered a 1 mg/ 50 ml dose, followed by killing 24 h later. For uricase intervention experiments during PM 10 and OVA co-exposure, groups of mice were exposed to intranasal saline, OVA (100 mg)/PM 10 (200 mg), or OVA (100 mg)/PM 10 (200 mg)/uricase (10 U) in fixed volumes of 50 ml phosphate-buffered saline on days 1, 3, and 5. All groups received intranasal challenge with OVA (100 mg per 50 ml) on days 21 and 22, followed by killing 24 h later. For ILC2 studies, groups of mice were exposed to intranasal saline, OVA (100 mg)/PM 10 (200 mg), or OVA (100 mg)/PM 10 (200 mg)/uricase (10 U) in fixed volumes of 50 ml phosphate-buffered saline on days 1, 3, and 5 and killed on day 6. For T-cell proliferation and Treg experiments in an adoptive transfer model, OTII CD4 T cells were isolated from spleens using a magnetic negative CD4 T-cell isolation kit (Stem Cell Technologies, Vancouver, British Columbia, Canada). CD4 þ T cells were quantified, CFSE labeled, and tail vein injected into C57BL/6 mice (1.5 Â 10 6 cells per mouse) followed by 24 h rest. The subsequent day, OTII recipient mice were exposed to intranasal saline, OVA (100 mg)/PM 10 (200 mg), or OVA (100 mg)/PM 10 (200 mg)/uricase (10 U) in 50 ml sterile saline. After 48 h draining mediastinal lymph nodes and control nondraining inguinal lymph nodes were collected for analysis of CD4 T-cell proliferation and quantification of Tregs.
Serum immunoglobulin analysis. Serum OVA-specific IgE, IgG1, and IgG2a were determined by ELISA. Serum dilutions were prepared and antibodies detected using HRP-conjugated anti-mouse IgG1 and IgG2a antibodies and biotin-conjugated anti-mouse IgE.
Real-time RT-PCR. Lung tissue was stored in RNAlater and homogenized in TRIzol using a TissueLyser II (Qiagen, Toronto, Ontario, Canada). Total RNA was extracted and cDNA was generated using a high capacity cDNA kit (Life Technologies, Mississauga, Ontario, Canada). Quantitative RT-PCR was performed on an ABI 7900HT RT-PCR machine (Applied Biosystems, Burlington, Ontario, Canada) using SYBR Green PCR master mix. Mouse gene expression was normalized to Actb using the following gene-specific primers: Actb, Statistical analysis. In vivo experiments were repeated in two to three independent trials with each trial having n ¼ 5-10 for a total of 10-15 animals. One-way ANOVAs were performed with a post hoc Bonferroni correction for multiple comparisons. A P-value of o0.05 was accepted to be a statistically significant difference between groups. Data were analyzed using GraphPad Software Version 4.0 (San Diego, CA).
Ethics approval. All human and animal experiments were approved by the University of British Columbia's Office of Research Services Ethics Committee or the University of Newcastle Animal Ethics Committee. For human sample collection, ethics approval and informed consent were obtained.
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